Informing relatives of heart or lung transplantation patients
The results of this qualitative study showed a gap between the information and support that relatives to newly listed heart or lung transplant patients need and receive. The professional teams and society in general must better understand the experiences, resources and challenges that the relatives face. More about this study Topics: Cardiovascular Nursing
ConclusionIn this single-center retrospective study, SIPAT did not predict cumulative re-admissions. Further study is required to validate SIPAT before clinical implementation.
Conclusion: This study demonstrates that organ transplant recipients, and especially children, are at increased risk of postoperative complications after cochlear implantation in comparison with healthy CI recipients.
The Stanford integrated psychosocial assessment for transplantation (SIPAT) is a validated psychosocial evaluation tool in the transplant population.
Patients with pulmonary hypertension (PH) due to chronic lung disease (Group 3 PH) have poor long-term outcomes. However, predictors of survival in Group 3 PH are not well described.
Adults with congenital heart disease (ACHD) represent a growing, albeit still small, proportion of heart transplant (HT) recipients (1, 2). These patients frequently present with complex anatomy and physiology, and atypical manifestations of cardiac failure. Despite being younger than other HT candidates, they have higher risk for adverse outcomes early after HT. This relates to prior thoracic operations, longer allograft ischemic time, a high prevalence of sensitization, less frequent use of pre-transplant mechanical circulatory support (1), and underappreciated end-organ dysfunction.
Lung transplant recipients are at very high risk of skin cancer. Omega-3 fatty acids (FAs) are anti-inflammatory and immune-modulating and potentially could reduce this risk. We assessed the feasibility of omega-3 FA supplementation to reduce skin cancer among these patients.
Waitlist mortality for lung transplant recipients continues to be a problem for transplant programs, with recent analysis from the UNOS database suggesting 14.7 percent of patients die or are delisted awaiting donor organ allocation.1 With the ongoing imbalance between graft supply and recipient demand, organ distribution policies have evolved to prioritize allocation to those patients with the least amount of time to live. In designing such allocation algorithms, four basic ethical principles are generally considered including patient autonomy, beneficence, non-maleficence and justice.
The US lung allocation system prioritizes allocation based upon medical urgency and benefit but does not address a federal mandate for broader geographic organ sharing. Whether broader geographic sharing of donor lungs would improve lung transplant waitlist outcomes is unknown.
Intralipid (ILP), a clinically used lipid emulsion, protects from cardiac ischemia reperfusion (I/R) injury by inhibiting opening of the mitochondrial permeability transition pore.1 This reduces reactive oxygen species (ROS) production.2 We hypothesized that ILP would also attenuate pulmonary I/R injury. Here we examine the effect of ILP on mediators of tissue damage in a rat pulmonary I/R model and on clinically relevant outcomes in a rat orthotopic lung transplantation model.
Publication date: Available online 12 September 2018Source: Heart &LungAuthor(s): Jared W. Davis, Gilbert J. Perry, Arka ChatterjeeAbstractVascular complications are rare but serious events following lung transplantation. Of the potential adverse events post lung transplant, pulmonary vein thrombosis is rare but often fatal. Our case describes a 54 year-old male who underwent single left lung transplantation and suddenly became hemodynamically unstable shortly after the procedure. The diagnosis of acute pulmonary vein thrombosis was made with the use of trans-esophageal echocardiography identifying complete occlusion o...